Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 97 entries
Sorted by: Best Match Show Resources per page
Combat Exposure and Risk of Suicide Attempt Among Danish Army Military Personnel.

The Journal of clinical psychiatry

Vedtofte MS, Elrond AF, Erlangsen A, Nielsen ABS, Stoltenberg CDG, Marott JL, Nissen LR, Madsen T.
PMID: 34644465
J Clin Psychiatry. 2021 Oct 12;82(6). doi: 10.4088/JCP.20m13251.

No abstract available.

Cite
Vedtofte MS, Elrond AF, Erlangsen A, et al. Combat Exposure and Risk of Suicide Attempt Among Danish Army Military Personnel. J Clin Psychiatry. 2021;82(6)doi: 10.4088/JCP.20m13251.
Vedtofte, M. S., Elrond, A. F., Erlangsen, A., Nielsen, A. B. S., Stoltenberg, C. D. G., Marott, J. L., Nissen, L. R., & Madsen, T. (2021). Combat Exposure and Risk of Suicide Attempt Among Danish Army Military Personnel. The Journal of clinical psychiatry, 82(6), . https://doi.org/10.4088/JCP.20m13251
Vedtofte, Mia S, et al. "Combat Exposure and Risk of Suicide Attempt Among Danish Army Military Personnel." The Journal of clinical psychiatry vol. 82,6 (2021). doi: https://doi.org/10.4088/JCP.20m13251
Vedtofte MS, Elrond AF, Erlangsen A, Nielsen ABS, Stoltenberg CDG, Marott JL, Nissen LR, Madsen T. Combat Exposure and Risk of Suicide Attempt Among Danish Army Military Personnel. J Clin Psychiatry. 2021 Oct 12;82(6). doi: 10.4088/JCP.20m13251. PMID: 34644465.
Copy Download .nbib Format: NLM
Combat Exposure and Risk of Suicide Attempt Among Danish Army Military Personnel.

The Journal of clinical psychiatry

Vedtofte MS, Elrond AF, Erlangsen A, Nielsen ABS, Stoltenberg CDG, Marott JL, Nissen LR, Madsen T.
PMID: 34644465
J Clin Psychiatry. 2021 Oct 12;82(6). doi: 10.4088/JCP.20m13251.

No abstract available.

Cite
Vedtofte MS, Elrond AF, Erlangsen A, et al. Combat Exposure and Risk of Suicide Attempt Among Danish Army Military Personnel. J Clin Psychiatry. 2021;82(6)doi: 10.4088/JCP.20m13251.
Vedtofte, M. S., Elrond, A. F., Erlangsen, A., Nielsen, A. B. S., Stoltenberg, C. D. G., Marott, J. L., Nissen, L. R., & Madsen, T. (2021). Combat Exposure and Risk of Suicide Attempt Among Danish Army Military Personnel. The Journal of clinical psychiatry, 82(6), . https://doi.org/10.4088/JCP.20m13251
Vedtofte, Mia S, et al. "Combat Exposure and Risk of Suicide Attempt Among Danish Army Military Personnel." The Journal of clinical psychiatry vol. 82,6 (2021). doi: https://doi.org/10.4088/JCP.20m13251
Vedtofte MS, Elrond AF, Erlangsen A, Nielsen ABS, Stoltenberg CDG, Marott JL, Nissen LR, Madsen T. Combat Exposure and Risk of Suicide Attempt Among Danish Army Military Personnel. J Clin Psychiatry. 2021 Oct 12;82(6). doi: 10.4088/JCP.20m13251. PMID: 34644465.
Copy Download .nbib Format: NLM
Major Histocompatibility Complex (MHC) Class I and MHC Class II Proteins: Conformational Plasticity in Antigen Presentation.

Frontiers in immunology

Wieczorek M, Abualrous ET, Sticht J, Álvaro-Benito M, Stolzenberg S, Noé F, Freund C.
PMID: 28367149
Front Immunol. 2017 Mar 17;8:292. doi: 10.3389/fimmu.2017.00292. eCollection 2017.

Antigen presentation by major histocompatibility complex (MHC) proteins is essential for adaptive immunity. Prior to presentation, peptides need to be generated from proteins that are either produced by the cell's own translational machinery or that are funneled into the...

Cite
Wieczorek M, Abualrous ET, Sticht J, et al. Major Histocompatibility Complex (MHC) Class I and MHC Class II Proteins: Conformational Plasticity in Antigen Presentation. Front Immunol. 2017;8:292doi: 10.3389/fimmu.2017.00292.
Wieczorek, M., Abualrous, E. T., Sticht, J., Álvaro-Benito, M., Stolzenberg, S., Noé, F., & Freund, C. (2017). Major Histocompatibility Complex (MHC) Class I and MHC Class II Proteins: Conformational Plasticity in Antigen Presentation. Frontiers in immunology, 8292. https://doi.org/10.3389/fimmu.2017.00292
Wieczorek, Marek, et al. "Major Histocompatibility Complex (MHC) Class I and MHC Class II Proteins: Conformational Plasticity in Antigen Presentation." Frontiers in immunology vol. 8 (2017): 292. doi: https://doi.org/10.3389/fimmu.2017.00292
Wieczorek M, Abualrous ET, Sticht J, Álvaro-Benito M, Stolzenberg S, Noé F, Freund C. Major Histocompatibility Complex (MHC) Class I and MHC Class II Proteins: Conformational Plasticity in Antigen Presentation. Front Immunol. 2017 Mar 17;8:292. doi: 10.3389/fimmu.2017.00292. eCollection 2017. PMID: 28367149; PMCID: PMC5355494.
Copy Download .nbib Format: NLM
The green fluorescent protein targets secretory proteins to the yeast vacuole .

Biochimica et biophysica acta

Adler K, Bernard J, Hensel G, Kohlwein SD, Kunze I, Kunze G, Neubohn B, Nilsson C, Stoltenburg R.
PMID: 10082794
Biochim Biophys Acta. 1999 Mar 09;1410(3):287-98. doi: 10.1016/s0005-2728(99)00006-7.
Free Article

The green fluorescent protein (GFP) was used as a marker to study the intracellular transport of vacuolar and secretory proteins in yeast. Therefore, the following gene constructs were expressed in Saccharomyces cerevisiae under control of the GAL1 promoter: GFP...

Cite
Adler K, Bernard J, Hensel G, et al. The green fluorescent protein targets secretory proteins to the yeast vacuole . Biochim Biophys Acta. 1999;1410(3):287-98doi: 10.1016/s0005-2728(99)00006-7.
Adler, K., Bernard, J., Hensel, G., Kohlwein, S. D., Kunze, I., Kunze, G., Neubohn, B., Nilsson, C., & Stoltenburg, R. (1999). The green fluorescent protein targets secretory proteins to the yeast vacuole . Biochimica et biophysica acta, 1410(3), 287-98. https://doi.org/10.1016/s0005-2728(99)00006-7
Adler, et al. "The green fluorescent protein targets secretory proteins to the yeast vacuole ." Biochimica et biophysica acta vol. 1410,3 (1999): 287-98. doi: https://doi.org/10.1016/s0005-2728(99)00006-7
Adler K, Bernard J, Hensel G, Kohlwein SD, Kunze I, Kunze G, Neubohn B, Nilsson C, Stoltenburg R. The green fluorescent protein targets secretory proteins to the yeast vacuole . Biochim Biophys Acta. 1999 Mar 09;1410(3):287-98. doi: 10.1016/s0005-2728(99)00006-7. PMID: 10082794.
Copy Download .nbib Format: NLM
Accurate mass determination of short-lived isotopes by a tandem Penning-trap mass spectrometer.

Physical review letters

Audi G, Becker S, Bollen G, Kern F, Kluge H, Moore RB, Otto T, Savard G, Schweikhard L, Stolzenberg H.
PMID: 10042782
Phys Rev Lett. 1990 Dec 17;65(25):3104-3107. doi: 10.1103/PhysRevLett.65.3104.

No abstract available.

Cite
Audi G, Becker S, Bollen G, et al. Accurate mass determination of short-lived isotopes by a tandem Penning-trap mass spectrometer. Phys Rev Lett. 1990;65(25):3104-3107doi: 10.1103/PhysRevLett.65.3104.
Audi, G., Becker, S., Bollen, G., Kern, F., Kluge, H., Moore, R. B., Otto, T., Savard, G., Schweikhard, L., & Stolzenberg, H. (1990). Accurate mass determination of short-lived isotopes by a tandem Penning-trap mass spectrometer. Physical review letters, 65(25), 3104-3107. https://doi.org/10.1103/PhysRevLett.65.3104
Audi, et al. "Accurate mass determination of short-lived isotopes by a tandem Penning-trap mass spectrometer." Physical review letters vol. 65,25 (1990): 3104-3107. doi: https://doi.org/10.1103/PhysRevLett.65.3104
Audi G, Becker S, Bollen G, Kern F, Kluge H, Moore RB, Otto T, Savard G, Schweikhard L, Stolzenberg H. Accurate mass determination of short-lived isotopes by a tandem Penning-trap mass spectrometer. Phys Rev Lett. 1990 Dec 17;65(25):3104-3107. doi: 10.1103/PhysRevLett.65.3104. PMID: 10042782.
Copy Download .nbib Format: NLM
Concomitant use of opioids and benzodiazepines in the outpatient setting: A retrospective study.

PM & R : the journal of injury, function, and rehabilitation

Simon J, Gehret J, Stolzenberg D, Beredjiklian PK, Teng J, Paskey T, Raju R.
PMID: 30243999
PM R. 2018 Sep 19; doi: 10.1016/j.pmrj.2018.09.026. Epub 2018 Sep 19.

BACKGROUND: Benzodiazepines have been identified as a concurrent factor in opioid related deaths. Although the dangers of concomitant administration of opioids and benzodiazepines are well documented, implementation of this knowledge into practice may be lagging behind.OBJECTIVE: To examine the...

Cite
Simon J, Gehret J, Stolzenberg D, et al. Concomitant use of opioids and benzodiazepines in the outpatient setting: A retrospective study. PM R. 2018;doi: 10.1016/j.pmrj.2018.09.026.
Simon, J., Gehret, J., Stolzenberg, D., Beredjiklian, P. K., Teng, J., Paskey, T., & Raju, R. (2018). Concomitant use of opioids and benzodiazepines in the outpatient setting: A retrospective study. PM & R : the journal of injury, function, and rehabilitation, . https://doi.org/10.1016/j.pmrj.2018.09.026
Simon, Jeremy, et al. "Concomitant use of opioids and benzodiazepines in the outpatient setting: A retrospective study." PM & R : the journal of injury, function, and rehabilitation vol. (2018). doi: https://doi.org/10.1016/j.pmrj.2018.09.026
Simon J, Gehret J, Stolzenberg D, Beredjiklian PK, Teng J, Paskey T, Raju R. Concomitant use of opioids and benzodiazepines in the outpatient setting: A retrospective study. PM R. 2018 Sep 19; doi: 10.1016/j.pmrj.2018.09.026. Epub 2018 Sep 19. PMID: 30243999.
Copy Download .nbib Format: NLM
Fatherhood alters gene expression within the MPOA.

Environmental epigenetics

Seelke AMH, Bond JM, Simmons TC, Joshi N, Settles ML, Stolzenberg D, Rhemtulla M, Bales KL.
PMID: 30568805
Environ Epigenet. 2018 Dec 12;4(4):dvy026. doi: 10.1093/eep/dvy026. eCollection 2018 Oct.

Female parenting is obligate in mammals, but fathering behavior among mammals is rare. Only 3-5% of mammalian species exhibit biparental care, including humans, and mechanisms of fathering behavior remain sparsely studied. However, in species where it does exist, paternal...

Cite
Seelke AMH, Bond JM, Simmons TC, et al. Fatherhood alters gene expression within the MPOA. Environ Epigenet. 2018;4(4):dvy026doi: 10.1093/eep/dvy026.
Seelke, A. M. H., Bond, J. M., Simmons, T. C., Joshi, N., Settles, M. L., Stolzenberg, D., Rhemtulla, M., & Bales, K. L. (2018). Fatherhood alters gene expression within the MPOA. Environmental epigenetics, 4(4), dvy026. https://doi.org/10.1093/eep/dvy026
Seelke, Adele M H, et al. "Fatherhood alters gene expression within the MPOA." Environmental epigenetics vol. 4,4 (2018): dvy026. doi: https://doi.org/10.1093/eep/dvy026
Seelke AMH, Bond JM, Simmons TC, Joshi N, Settles ML, Stolzenberg D, Rhemtulla M, Bales KL. Fatherhood alters gene expression within the MPOA. Environ Epigenet. 2018 Dec 12;4(4):dvy026. doi: 10.1093/eep/dvy026. eCollection 2018 Oct. PMID: 30568805; PMCID: PMC6305489.
Copy Download .nbib Format: NLM
Nomi Maya Stolzenberg Responds.

Journal of the American Psychoanalytic Association

Stolzenberg NM.
PMID: 34424073
J Am Psychoanal Assoc. 2021 Jun;69(3):673-675. doi: 10.1177/00030651211030179.

No abstract available.

Cite
Stolzenberg NM. Nomi Maya Stolzenberg Responds. J Am Psychoanal Assoc. 2021;69(3):673-675doi: 10.1177/00030651211030179.
Stolzenberg, N. M. (2021). Nomi Maya Stolzenberg Responds. Journal of the American Psychoanalytic Association, 69(3), 673-675. https://doi.org/10.1177/00030651211030179
Stolzenberg, Nomi Maya. "Nomi Maya Stolzenberg Responds." Journal of the American Psychoanalytic Association vol. 69,3 (2021): 673-675. doi: https://doi.org/10.1177/00030651211030179
Stolzenberg NM. Nomi Maya Stolzenberg Responds. J Am Psychoanal Assoc. 2021 Jun;69(3):673-675. doi: 10.1177/00030651211030179. PMID: 34424073.
Copy Download .nbib Format: NLM
Gene replacement therapy with onasemnogene abeparvovec in children with spinal muscular atrophy aged 24 months or younger and bodyweight up to 15 kg: an observational cohort study.

The Lancet. Child & adolescent health

Weiß C, Ziegler A, Becker LL, Johannsen J, Brennenstuhl H, Schreiber G, Flotats-Bastardas M, Stoltenburg C, Hartmann H, Illsinger S, Denecke J, Pechmann A, Müller-Felber W, Vill K, Blaschek A, Smitka M, van der Stam L, Weiss K, Winter B, Goldhahn K, Plecko B, Horber V, Bernert G, Husain RA, Rauscher C, Trollmann R, Garbade SF, Hahn A, von der Hagen M, Kaindl AM.
PMID: 34756190
Lancet Child Adolesc Health. 2021 Oct 28; doi: 10.1016/S2352-4642(21)00287-X. Epub 2021 Oct 28.

BACKGROUND: Given the novelty of gene replacement therapy with onasemnogene abeparvovec in spinal muscular atrophy, efficacy and safety data are limited, especially for children older than 24 months, those weighing more than 8·5 kg, and those who have received...

Cite
Weiß C, Ziegler A, Becker LL, et al. Gene replacement therapy with onasemnogene abeparvovec in children with spinal muscular atrophy aged 24 months or younger and bodyweight up to 15 kg: an observational cohort study. Lancet Child Adolesc Health. 2021;doi: 10.1016/S2352-4642(21)00287-X.
Weiß, C., Ziegler, A., Becker, L. L., Johannsen, J., Brennenstuhl, H., Schreiber, G., Flotats-Bastardas, M., Stoltenburg, C., Hartmann, H., Illsinger, S., Denecke, J., Pechmann, A., Müller-Felber, W., Vill, K., Blaschek, A., Smitka, M., van der Stam, L., Weiss, K., Winter, B., Goldhahn, K., Plecko, B., Horber, V., Bernert, G., Husain, R. A., Rauscher, C., Trollmann, R., Garbade, S. F., Hahn, A., von der Hagen, M., & Kaindl, A. M. (2021). Gene replacement therapy with onasemnogene abeparvovec in children with spinal muscular atrophy aged 24 months or younger and bodyweight up to 15 kg: an observational cohort study. The Lancet. Child & adolescent health, . https://doi.org/10.1016/S2352-4642(21)00287-X
Weiß, Claudia, et al. "Gene replacement therapy with onasemnogene abeparvovec in children with spinal muscular atrophy aged 24 months or younger and bodyweight up to 15 kg: an observational cohort study." The Lancet. Child & adolescent health vol. (2021). doi: https://doi.org/10.1016/S2352-4642(21)00287-X
Weiß C, Ziegler A, Becker LL, Johannsen J, Brennenstuhl H, Schreiber G, Flotats-Bastardas M, Stoltenburg C, Hartmann H, Illsinger S, Denecke J, Pechmann A, Müller-Felber W, Vill K, Blaschek A, Smitka M, van der Stam L, Weiss K, Winter B, Goldhahn K, Plecko B, Horber V, Bernert G, Husain RA, Rauscher C, Trollmann R, Garbade SF, Hahn A, von der Hagen M, Kaindl AM. Gene replacement therapy with onasemnogene abeparvovec in children with spinal muscular atrophy aged 24 months or younger and bodyweight up to 15 kg: an observational cohort study. Lancet Child Adolesc Health. 2021 Oct 28; doi: 10.1016/S2352-4642(21)00287-X. Epub 2021 Oct 28. PMID: 34756190.
Copy Download .nbib Format: NLM
TRAPing Ghrelin-Activated Circuits: A Novel Tool to Identify, Target and Control Hormone-Responsive Populations in TRAP2 Mice.

International journal of molecular sciences

Stoltenborg I, Peris-Sampedro F, Schéle E, Le May MV, Adan RAH, Dickson SL.
PMID: 35008985
Int J Mol Sci. 2022 Jan 05;23(1). doi: 10.3390/ijms23010559.

The availability of Cre-based mouse lines for visualizing and targeting populations of hormone-sensitive cells has helped identify the neural circuitry driving hormone effects. However, these mice have limitations and may not even be available. For instance, the development of...

Cite
Stoltenborg I, Peris-Sampedro F, Schéle E, et al. TRAPing Ghrelin-Activated Circuits: A Novel Tool to Identify, Target and Control Hormone-Responsive Populations in TRAP2 Mice. Int J Mol Sci. 2022;23(1)doi: 10.3390/ijms23010559.
Stoltenborg, I., Peris-Sampedro, F., Schéle, E., Le May, M. V., Adan, R. A. H., & Dickson, S. L. (2022). TRAPing Ghrelin-Activated Circuits: A Novel Tool to Identify, Target and Control Hormone-Responsive Populations in TRAP2 Mice. International journal of molecular sciences, 23(1), . https://doi.org/10.3390/ijms23010559
Stoltenborg, Iris, et al. "TRAPing Ghrelin-Activated Circuits: A Novel Tool to Identify, Target and Control Hormone-Responsive Populations in TRAP2 Mice." International journal of molecular sciences vol. 23,1 (2022). doi: https://doi.org/10.3390/ijms23010559
Stoltenborg I, Peris-Sampedro F, Schéle E, Le May MV, Adan RAH, Dickson SL. TRAPing Ghrelin-Activated Circuits: A Novel Tool to Identify, Target and Control Hormone-Responsive Populations in TRAP2 Mice. Int J Mol Sci. 2022 Jan 05;23(1). doi: 10.3390/ijms23010559. PMID: 35008985.
Copy Download .nbib Format: NLM
Validity and Reliability of the German Version of the CP QOL-Child and CP QOL-Teen Questionnaire.

Neuropediatrics

Maier M, Stoltenburg C, Sarpong-Bengelsdorf A, Lebek S.
PMID: 34879423
Neuropediatrics. 2021 Dec 08; doi: 10.1055/s-0041-1740377. Epub 2021 Dec 08.

The aim of the study was to determine the psychometric properties of the German version of the Cerebral Palsy Quality of Life Questionnaire for Children and Adolescents (CP QOL-Child and -Teen). It is a condition-specific questionnaire with a self-report...

Cite
Maier M, Stoltenburg C, Sarpong-Bengelsdorf A, et al. Validity and Reliability of the German Version of the CP QOL-Child and CP QOL-Teen Questionnaire. Neuropediatrics. 2021;doi: 10.1055/s-0041-1740377.
Maier, M., Stoltenburg, C., Sarpong-Bengelsdorf, A., & Lebek, S. (2021). Validity and Reliability of the German Version of the CP QOL-Child and CP QOL-Teen Questionnaire. Neuropediatrics, . https://doi.org/10.1055/s-0041-1740377
Maier, Manuel, et al. "Validity and Reliability of the German Version of the CP QOL-Child and CP QOL-Teen Questionnaire." Neuropediatrics vol. (2021). doi: https://doi.org/10.1055/s-0041-1740377
Maier M, Stoltenburg C, Sarpong-Bengelsdorf A, Lebek S. Validity and Reliability of the German Version of the CP QOL-Child and CP QOL-Teen Questionnaire. Neuropediatrics. 2021 Dec 08; doi: 10.1055/s-0041-1740377. Epub 2021 Dec 08. PMID: 34879423.
Copy Download .nbib Format: NLM
Gene replacement therapy with onasemnogene abeparvovec in children with spinal muscular atrophy aged 24 months or younger and bodyweight up to 15 kg: an observational cohort study.

The Lancet. Child & adolescent health

Weiß C, Ziegler A, Becker LL, Johannsen J, Brennenstuhl H, Schreiber G, Flotats-Bastardas M, Stoltenburg C, Hartmann H, Illsinger S, Denecke J, Pechmann A, Müller-Felber W, Vill K, Blaschek A, Smitka M, van der Stam L, Weiss K, Winter B, Goldhahn K, Plecko B, Horber V, Bernert G, Husain RA, Rauscher C, Trollmann R, Garbade SF, Hahn A, von der Hagen M, Kaindl AM.
PMID: 34756190
Lancet Child Adolesc Health. 2022 Jan;6(1):17-27. doi: 10.1016/S2352-4642(21)00287-X. Epub 2021 Oct 29.

BACKGROUND: Given the novelty of gene replacement therapy with onasemnogene abeparvovec in spinal muscular atrophy, efficacy and safety data are limited, especially for children older than 24 months, those weighing more than 8·5 kg, and those who have received...

Cite
Weiß C, Ziegler A, Becker LL, et al. Gene replacement therapy with onasemnogene abeparvovec in children with spinal muscular atrophy aged 24 months or younger and bodyweight up to 15 kg: an observational cohort study. Lancet Child Adolesc Health. 2021;6(1):17-27doi: 10.1016/S2352-4642(21)00287-X.
Weiß, C., Ziegler, A., Becker, L. L., Johannsen, J., Brennenstuhl, H., Schreiber, G., Flotats-Bastardas, M., Stoltenburg, C., Hartmann, H., Illsinger, S., Denecke, J., Pechmann, A., Müller-Felber, W., Vill, K., Blaschek, A., Smitka, M., van der Stam, L., Weiss, K., Winter, B., Goldhahn, K., Plecko, B., Horber, V., Bernert, G., Husain, R. A., Rauscher, C., Trollmann, R., Garbade, S. F., Hahn, A., von der Hagen, M., & Kaindl, A. M. (2022). Gene replacement therapy with onasemnogene abeparvovec in children with spinal muscular atrophy aged 24 months or younger and bodyweight up to 15 kg: an observational cohort study. The Lancet. Child & adolescent health, 6(1), 17-27. https://doi.org/10.1016/S2352-4642(21)00287-X
Weiß, Claudia, et al. "Gene replacement therapy with onasemnogene abeparvovec in children with spinal muscular atrophy aged 24 months or younger and bodyweight up to 15 kg: an observational cohort study." The Lancet. Child & adolescent health vol. 6,1 (2022): 17-27. doi: https://doi.org/10.1016/S2352-4642(21)00287-X
Weiß C, Ziegler A, Becker LL, Johannsen J, Brennenstuhl H, Schreiber G, Flotats-Bastardas M, Stoltenburg C, Hartmann H, Illsinger S, Denecke J, Pechmann A, Müller-Felber W, Vill K, Blaschek A, Smitka M, van der Stam L, Weiss K, Winter B, Goldhahn K, Plecko B, Horber V, Bernert G, Husain RA, Rauscher C, Trollmann R, Garbade SF, Hahn A, von der Hagen M, Kaindl AM. Gene replacement therapy with onasemnogene abeparvovec in children with spinal muscular atrophy aged 24 months or younger and bodyweight up to 15 kg: an observational cohort study. Lancet Child Adolesc Health. 2022 Jan;6(1):17-27. doi: 10.1016/S2352-4642(21)00287-X. Epub 2021 Oct 29. PMID: 34756190.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 97 entries